A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera(®)) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)

BACKGROUND: Biosimilars are highly similar to the licensed biologic (“reference product”), with no clinically meaningful differences in safety, purity, or potency between the two products. OBJECTIVE: This comparative 52-week clinical study evaluated the efficacy, safety, immunogenicity, pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharman, Jeff P., Liberati, Anna Marina, Ishizawa, Kenichi, Khan, Tahira, Robbins, Jeffery, Alcasid, Ann, Rosenberg, Julie Ann, Aurer, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113218/
https://www.ncbi.nlm.nih.gov/pubmed/31820339
http://dx.doi.org/10.1007/s40259-019-00398-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113218/
https://www.ncbi.nlm.nih.gov/pubmed/31820339
http://dx.doi.org/10.1007/s40259-019-00398-7

Ejemplares similares